293 related articles for article (PubMed ID: 24994926)
1. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
Hopp K; Hommerding CJ; Wang X; Ye H; Harris PC; Torres VE
J Am Soc Nephrol; 2015 Jan; 26(1):39-47. PubMed ID: 24994926
[TBL] [Abstract][Full Text] [Related]
2. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
3. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1
Arroyo J; Escobar-Zarate D; Wells HH; Constans MM; Thao K; Smith JM; Sieben CJ; Martell MR; Kline TL; Irazabal MV; Torres VE; Hopp K; Harris PC
Kidney Int; 2021 Jun; 99(6):1392-1407. PubMed ID: 33705824
[TBL] [Abstract][Full Text] [Related]
4. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
5. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
[TBL] [Abstract][Full Text] [Related]
6. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
7. Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Sekine A; Hoshino J; Fujimaru T; Suwabe T; Mizuno H; Kawada M; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Mandai S; Chiga M; Kikuchi H; Ando F; Mori T; Sohara E; Uchida S; Sawa N; Takaichi K; Ubara Y
Am J Nephrol; 2020; 51(9):745-751. PubMed ID: 32784291
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
9. CD8
Kleczko EK; Marsh KH; Tyler LC; Furgeson SB; Bullock BL; Altmann CJ; Miyazaki M; Gitomer BY; Harris PC; Weiser-Evans MCM; Chonchol MB; Clambey ET; Nemenoff RA; Hopp K
Kidney Int; 2018 Dec; 94(6):1127-1140. PubMed ID: 30249452
[TBL] [Abstract][Full Text] [Related]
10. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
[TBL] [Abstract][Full Text] [Related]
11. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease.
Di Mise A; Wang X; Ye H; Pellegrini L; Torres VE; Valenti G
FASEB J; 2021 Oct; 35(10):e21874. PubMed ID: 34486176
[TBL] [Abstract][Full Text] [Related]
13. [Tolvaptan, a vasopressin V
Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
[TBL] [Abstract][Full Text] [Related]
14. Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.
Trant J; Sanchez G; McDermott JP; Blanco G
Am J Physiol Renal Physiol; 2023 Dec; 325(6):F857-F869. PubMed ID: 37823195
[TBL] [Abstract][Full Text] [Related]
15. Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion.
Wilk EJ; Howton TC; Fisher JL; Oza VH; Brownlee RT; McPherson KC; Cleary HL; Yoder BK; George JF; Mrug M; Lasseigne BN
Mol Med; 2023 May; 29(1):67. PubMed ID: 37217845
[TBL] [Abstract][Full Text] [Related]
16. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease.
Wang X; Jiang L; Thao K; Sussman CR; LaBranche T; Palmer M; Harris PC; McKnight GS; Hoeflich KP; Schalm S; Torres VE
J Am Soc Nephrol; 2022 Jun; 33(6):1087-1104. PubMed ID: 35236775
[TBL] [Abstract][Full Text] [Related]
17. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Zhang C; Balbo B; Ma M; Zhao J; Tian X; Kluger Y; Somlo S
J Am Soc Nephrol; 2021 Jan; 32(1):41-51. PubMed ID: 33046531
[TBL] [Abstract][Full Text] [Related]
19. Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease.
Arkhipov SN; Potter DL; Sultanova RF; Ilatovskaya DV; Harris PC; Pavlov TS
Physiol Rep; 2023 Apr; 11(7):e15652. PubMed ID: 37024297
[TBL] [Abstract][Full Text] [Related]
20. Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.
Gilbert RD; Evans H; Olalekan K; Nagra A; Haq MR; Griffiths M
Pediatr Nephrol; 2017 May; 32(5):893-896. PubMed ID: 28194574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]